Incyte Corporation (LON:0J9P)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 9.30B |
| Revenue (ttm) | 3.42B |
| Net Income (ttm) | 16.46M |
| Shares Out | n/a |
| EPS (ttm) | 0.08 |
| PE Ratio | 564.91 |
| Forward PE | 10.70 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 56 |
| Average Volume | 464 |
| Open | 64.84 |
| Previous Close | 64.74 |
| Day's Range | 64.20 - 64.84 |
| 52-Week Range | 53.61 - 83.54 |
| Beta | 0.68 |
| RSI | 60.54 |
| Earnings Date | Apr 29, 2025 |
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib... [Read more]
Financial Performance
In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.
Financial numbers in USD Financial StatementsNews
Incyte gets expanded FDA approval for Zynyz in anal cancer
FDA gave expanded approval for Incyte's Zynyz in treating metastatic anal cancer. Read more here.
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--FDA Approves Zynyz (retifanlimab-dlwr) the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States.
Incyte and Novartis settle royalties dispute related to Jakafi
20 stocks of companies showing excellent earnings-season trends even as the economy cools
With U.S. economic growth turning negative during the first quarter, this earnings season's results might shed some light on which companies may best weather the disruption brought about by President ...
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Incyte to Present at Upcoming Investor Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the 2025 BofA Securities Health Care Conference on Tuesday, May 13, 2025 at 1:40 pm (PDT). The presentat...
Incyte Corporation 2025 Q1 - Results - Earnings Call Presentation
Incyte raises 2025 Jakafi revenue guidance to $3B amid strong Q1 growth
Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ETCompany ParticipantsGreg Shertzer - Director of Investor...
Incyte raises 2025 sales forecast for blood cancer drug after solid quarter
Incyte Corp raised its annual sales forecast for its blood cancer treatment Jakafi on Tuesday, after robust sales of the drug helped it beat Wall Street estimates for quarterly results.
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs.
Earnings Scheduled For April 29, 2025
Companies Reporting Before The Bell • First Commonwealth (NYSE: FCF) is estimated to report quarterly earnings at $0.32 per share on revenue of $117.60 million. • CommVault Systems (NASDAQ: CVLT) is...
Incyte Q1 2025 Earnings Preview
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AACR25--Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025.
Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASCO25--Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Incyte (INCY) Sees Boosted Price Target by BofA Analyst | INCY Stock News
Incyte (INCY) Sees Boosted Price Target by BofA Analyst | INCY Stock News
Incyte (INCY) Revenue Surges, But Stock Drops 20%
Incyte (INCY) Revenue Surges, But Stock Drops 20%
Incyte to Report First Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 29, 20...
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
These 20 worst-performing stocks in the S&P 500 sank 17% or more in March
Stocks turned higher on Monday afternoon to finish March on a positive note. Still, the S&P 500 ended with a 5.8% decline for March, with 69% of component stocks down for the month.
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitam...
Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib
This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Incyte downgraded to Neutral at Guggenheim on trial results for skin disease treatment
Incyte (INCY) was downgraded to Neutral from Buy at Guggenheim. Read more here.
Incyte (INCY) Stock Drops on Phase Three Trial Data
Incyte (INCY) Stock Drops on Phase Three Trial Data